Tempus AI rises as partnership momentum and $1.1B+ contract backlog support sentiment
Tempus AI (TEM) is moving higher as investors react to renewed optimism around its partner-driven oncology pipeline and expanding contracted backlog. Recent catalysts include a Daiichi Sankyo cancer-drug partnership and a disclosed record total contract value topping $1.1 billion as of Dec. 31, 2025.
1. What’s moving the stock
Tempus AI shares are trading higher in the latest session, with buying interest leaning on recent, company-specific momentum in its biopharma collaborations and contracted backlog. In late March 2026, the stock drew attention after news of a partnership with Daiichi Sankyo tied to cancer-drug development, a headline that helped support sentiment around Tempus’ data and AI-enabled oncology platform. (sahmcapital.com)
2. The fundamental bull case traders are leaning on
Tempus has been emphasizing contract and partnership expansion as a leading indicator for future revenue. In February 2026, the company disclosed record Total Contract Value of more than $1.1 billion as of December 31, 2025, reinforcing the narrative that biopharma and health-system demand is translating into multi-year commercial commitments. (investors.tempus.com)
3. Additional support from the Street
Recent analyst activity has also helped keep attention on the name. In March 2026, Tempus was cited as moving higher after an analyst reiterated a Buy rating with a $75 price target, adding to the flow of research commentary that has been a recurring driver of short-term moves in TEM. (cdn3.benzinga.com)
4. What to watch next
Investors will be watching for more detail on the scope, economics, and timelines of new and existing biopharma collaborations—especially whether they expand data licensing, trial enablement, and diagnostic pull-through. Traders will also monitor whether contract metrics convert cleanly into reported revenue growth and improving profitability metrics over upcoming quarters.